Literature DB >> 20610640

Shock in acute myocardial infarction: the Cape Horn for trials?

Holger Thiele1, Bachir Allam, Gilles Chatellier, Gerhard Schuler, Antoine Lafont.   

Abstract

Despite therapeutic improvements, cardiogenic shock (CS) remains the most common cause of death in patients with acute myocardial infarction (AMI). In addition to percutaneous coronary intervention, inotropes, fluids, adjunctive medication, intra-aortic balloon counterpulsation, and also assist devices are widely used for treatment. However, currently, there is only limited evidence for any of the above treatments. This review will therefore outline the underlying causes, pathophysiology, and treatment of CS complicating AMI with major focus on interventional techniques and advancement of new therapeutical arsenals, both pharmacological and mechanical.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20610640     DOI： 10.1093/eurheartj/ehq220

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


  47 in total

1.  Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy.

Authors:  Christian Jung; Georg Fuernau; Suzanne de Waha; Ingo Eitel; Steffen Desch; Gerhard Schuler; Hans R Figulla; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2015-02-27       Impact factor: 5.460

Review 2.  Cellular responses to mild heat stress.

Authors:  H G Park; S I Han; S Y Oh; H S Kang
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

Review 3.  Phagocytosis of apoptotic cells: a matter of balance.

Authors:  C J G de Almeida; R Linden
Journal:  Cell Mol Life Sci       Date:  2005-07       Impact factor: 9.261

4.  Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock.

Authors:  David D Berg; Devraj Sukul; Molly O'Brien; Benjamin M Scirica; Piotr S Sobieszczyk; Benjamin A Olenchock; Erin A Bohula; David A Morrow
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2015-04-30

5.  Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes.

Authors:  Hiroo Takayama; Lori Soni; Bindu Kalesan; Lauren K Truby; Takeyoshi Ota; Sophia Cedola; Zain Khalpey; Nir Uriel; Paolo Colombo; Donna M Mancini; Ulrich P Jorde; Yoshifumi Naka
Journal:  Circ Heart Fail       Date:  2014-07-15       Impact factor: 8.790

Review 6.  [Mechanical support in cardiogenic shock].

Authors:  T Graf; H Thiele
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

7.  What is extracorporeal cardiopulmonary resuscitation?

Authors:  Federico Pappalardo; Andrea Montisci
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 8.  [Cardiogenic shock : Current evidence].

Authors:  H Thiele
Journal:  Herz       Date:  2017-12       Impact factor: 1.443

9.  Real-world clinical experience with the percutaneous extracorporeal life support system: Results from the German Lifebridge® Registry.

Authors:  Maryna Masyuk; Peter Abel; Martin Hug; Bernhard Wernly; Assad Haneya; Stefan Sack; Konstantinos Sideris; Nicolas Langwieser; Tobias Graf; Georg Fuernau; Marcus Franz; Ralf Westenfeld; Malte Kelm; Stephan B Felix; Christian Jung
Journal:  Clin Res Cardiol       Date:  2019-04-26       Impact factor: 5.460

10.  Predictors of mortality in patients with cardiogenic shock treated with primary percutaneous coronary intervention and intra-aortic balloon counterpulsation.

Authors:  B Schwarz; M Abdel-Wahab; D R Robinson; G Richardt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-23       Impact factor: 0.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.